Bio-Optronics Inks $30M Growth Investment

Bio-Optronics today announced a $30 million investment by Mainsail Partners, a growth equity firm that invests in fast-growing bootstrapped technology companies. Mainsail will partner with Dan Kerpelman, Chief Executive Officer, and the existing management team to quickly scale up the business. Bio-Optronics will use capital and support from Mainsail to accelerate product development, improve customer service and increase sales and marketing.

Bio-Optronics is a software provider for healthcare organizations. The company’s product suite includes Clinical Conductor, the leading Clinical Trial Management System (CTMS), Momentum, which enables rapid, automated and accurate scheduling of medical staff, and Biopoint, which enhances patient safety and streamlines patient workflow. Customers include leading hospital systems, clinical research centers and organizations, medical groups, and the Department of Veterans Affairs.

“Our business is based on providing exceptional customer support to great software products,” said Dan Kerpelman. “We did not need to raise capital to continue our growth, but rather to partner with Mainsail in order to invest more heavily in our products and in the success of our customers. Mainsail has taken the time and effort to develop a relationship with the company over the last few years, and I am confident that they will add meaningful value. “That’s right.

Michael Anderson, Partner at Mainsail Partners, said, “We are very pleased to be working with Dan and the Bio-Optronics team. Over the years, they have demonstrated the ability to develop compelling new products and features for the global market, a dedicated focus on serving their customers, and a track record of strong growth. Anderson added, “The company’s Clinical Conductor product should benefit from continued growth in the number and complexity of clinical trials, and the Momentum Scheduling Product should continue to grow rapidly as healthcare organizations manually stop building medical staff schedules and instead use software to help automate the process. “That’s right.

Apart from Mr. Anderson, Taylor McKinley, Mainsail Operating Partner, and David Farsai, Mainsail Vice President, will join Dan Kerpelman on the Board of Directors of the company.

On Bio-Optronics
Bio-Optronics is a leading software and services company that creates user-focused applications for healthcare organizations that have a positive impact on business performance. With applications focused on clinical research, automated resource utilization and patient safety, Bio-Optronics software is used by thousands of healthcare organizations worldwide to simplify complex business processes and improve overall quality and efficiency.

Visit http://www for more information. Biooptronics Come or follow @BioOptronics on Twitter or LinkedIn

Mainsail Partners
Mainsail Partners is a San Francisco-based growth equity firm investing in bootstrapped software companies. For 15 years, the company has partnered with exceptional founders and entrepreneurs across a wide range of end-users. Mainsail has a team of experienced operating professionals to help entrepreneurs scale their businesses and accelerate their growth. The company has raised more than $750 million in committed capital Visit http://www for more information. Major Sail Partners Come on,

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Bio-Optronics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co